Enoximone sulfoxide | CAS# 83982-78-9 | Biochemical

MedKoo Cat#: 576981 | Name: Enoximone sulfoxide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enoximone sulfoxide is a selective phosphodiesterase III (PDE3) inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. Enoximone prevents the degradation of cAMP by PDE, which prolongs signal transduction and its subsequent effects. It is used in patients with congestive heart failure.

Chemical Structure

Enoximone sulfoxide

CAS#83982-78-9

Theoretical Analysis

MedKoo Cat#: 576981

Name: Enoximone sulfoxide

CAS#: 83982-78-9

Chemical Formula: C12H12N2O3S

Exact Mass: 264.0569

Molecular Weight: 264.30

Elemental Analysis: C, 54.53; H, 4.58; N, 10.60; O, 18.16; S, 12.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Enoximone sulfoxide; Mdl17043 sulfoxide; Mdl-17043 sulfoxide; Mdl 17043 sulfoxide

IUPAC/Chemical Name

4-methyl-5-(4-(methylsulfinyl)benzoyl)-1,3-dihydro-2H-imidazol-2-one

InChi Key

XHRYEIRXTWSXAE-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H12N2O3S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(6-4-8)18(2)17/h3-6H,1-2H3,(H2,13,14,16)

SMILES Code

CC1=C(NC(=O)N1)C(=O)c2ccc(cc2)S(=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 264.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H, Ouyang Z, Xu X, Wang W, Fan Q, Tang T, Qin A, Dai K. The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 2014 Jul;35(22):5721-30. doi: 10.1016/j.biomaterials.2014.04.006. Epub 2014 Apr 22. PubMed PMID: 24767789. 2: Rivera MF, Chukkapalli SS, Velsko IM, Lee JY, Bhattacharyya I, Dolce C, Toro EJ, Holliday LS, Kesavalu L. Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis. PLoS One. 2014 Mar 17;9(3):e92119. doi: 10.1371/journal.pone.0092119. eCollection 2014. PubMed PMID: 24638087; PubMed Central PMCID: PMC3956892. 3: Sousa E, Graça I, Baptista T, Vieira FQ, Palmeira C, Henrique R, Jerónimo C. Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics. 2013 May;8(5):548-58. doi: 10.4161/epi.24519. Epub 2013 Apr 17. PubMed PMID: 23644875; PubMed Central PMCID: PMC3741225. 4: Toro EJ, Zuo J, Ostrov DA, Catalfamo D, Bradaschia-Correa V, Arana-Chavez V, Caridad AR, Neubert JK, Wronski TJ, Wallet SM, Holliday LS. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem. 2012 May 18;287(21):17894-904. doi: 10.1074/jbc.M111.280511. Epub 2012 Apr 2. PubMed PMID: 22474295; PubMed Central PMCID: PMC3366803. 5: Toro EJ, Ostrov DA, Wronski TJ, Holliday LS. Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor. Curr Protein Pept Sci. 2012 Mar;13(2):180-91. Review. PubMed PMID: 22044158; PubMed Central PMCID: PMC3409362. 6: Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. doi: 10.1073/pnas.1014720108. Epub 2011 Feb 28. PubMed PMID: 21368194; PubMed Central PMCID: PMC3060242.